

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### INTERACTION OF LNA OLIGONUCLEOTIDES WITH MDR1 PROMOTER

E. L. Chernolovskaya<sup>a</sup>; A. A. Koshkin; V. V. Vlassov<sup>a</sup>

<sup>a</sup> Novosibirsk Institute of Bioorganic Chemistry, Novosibirsk, Russia

Online publication date: 31 March 2001

**To cite this Article** Chernolovskaya, E. L. , Koshkin, A. A. and Vlassov, V. V.(2001) 'INTERACTION OF LNA OLIGONUCLEOTIDES WITH MDR1 PROMOTER', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 847 — 850

**To link to this Article:** DOI: 10.1081/NCN-100002443

**URL:** <http://dx.doi.org/10.1081/NCN-100002443>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## INTERACTION OF LNA OLIGONUCLEOTIDES WITH MDR1 PROMOTER

E. L. Chernolovskaya,<sup>1,\*</sup> A. A. Koshkin,<sup>2</sup> and V. V. Vlassov<sup>1</sup>

<sup>1</sup>Novosibirsk Institute of Bioorganic Chemistry, Lavrentiev ave.,  
8, Novosibirsk, 630090, Russia

<sup>2</sup>Exiqon A/S, Bygstubben 9, DK-2950 Vedbaek, Denmark


### ABSTRACT

LNA oligonucleotides [1] can be used for targetting to double stranded DNA by the "strand invasion" mechanism. We used affinity modification by reactive oligonucleotide conjugates for investigation of oligonucleotides interaction with structured DNA. The tested LNAs and oligonucleotides of the same sequence were assayed as anti-mdr1 drugs in different cell cultures. One of the oligos, LNA79 strongly inhibited mdr1 induction in Hela cells and totally prevented activation of mdr1 in K-562.

We have investigated binding of oligonucleotides and strong binding oligonucleotide analogus, locked nucleic acids (LNA) to different regions of the mdr1 promoter sequences. The term "Locked Nucleic Acids" has been used to emphasize that the usual conformational freedom of the furanose ring in standard nucleosides is restricted in LNA by a methylene linker that connects the 2'-O position to the 4'-C position. LNA78 is complementary to the A:T rich low melting point region near the heat shock response element, LNA77 is complementary to the G:C rich region within important regulatory region of the mdr1 activator binding site and LNA79 is complementary to the region capable of alternative hairpin formation near the start of transcription.

---

\*Corresponding author. E-mail: elena\_ch@niboch.nsc.ru



**Figure 1.** Gel-shift analysis of oligonucleotides binding to pMDRCAT5 plasmid.


**LNA 77:** pCGCCCCGGCGCdt

**LNA78:** pATTTCAACTTATGTAGda

**LNA79:** pTAGTGGAAAGAdc

A, G, T and C represent adenine, guanine, thymine and 5-methylcytosine LNA monomers, da, dc and dt—deoxyriboadenosine, cytidine and thymidine respectively.

We investigated the interaction of LNAs and ODNs of the same sequences with *mdr1* promoter sequences in relaxed and supercoiled plasmid pMDRCAT5, containing –258/+121 region of *mdr1* promoter sequence. This region was shown to be responsible for activation by heat shock, UV-irradiation and some therapeutics




**Figure 2.** Primer extension analysis of chemical crosslinking of reactive derivatives to pMDRCAT5 plasmid. Lanes 1, 3, 5, 7—plasmid cleaved by Pst I prior to alkylation, lanes 2, 4, 6—circular plasmid. The plasmids were incubated with  $10^{-6}$ M RCI-derivatives of LNAs or ODNs in TE buffer for 18 hours. Modified residues were converted to strand breaks by piperidine treatment. Cleavage positions were determined by primer extension.

[2]. The results of gel-shift analysis (Fig. 1) indicate that all tested LNAs bind to the relaxed plasmide whereas ODNs of the same sequence do not demonstrate substantial binding to the DNA.


The specificity of LNAs binding was assayed using the affinity modification method, with reactive conjugates of the oligonucleotides, bearing the alkylating group tethered to the 5'-phosphate end. Results of the experiment shown in Figure 2 indicate no detectable non specific cleavage. The reactive derivative of LNA 79 efficiently cleaves the DNA both in linear and in circular plasmids. The reactive derivative of LNA 77 demonstrates less efficient cleavage especially in the undigested plasmid. The data correlate with binding efficiencies of the oligonucleotides (Fig. 2).

The data (Fig. 3) demonstrate, that the reactive derivative of LNA79 alkylates the third base (cytosine 73) from the end of the target sequence. This position specificity of the reaction suggests that LNA-DNA complex has A-form conformation.


We have assayed LNAs and ODNs as anti-mdr1 compounds in cell culture. As it is seen from the data shown in Figures 4,5, doxorubicine induces mdr1 RNA synthesis in K562 cells and all used cytostatics activate mdr1 synthesis in Hela cells. From the data, shown in Figure 3 it is seen, that LNA79 strongly inhibits mdr1 induction in Hela cells and totally prevents activation of mdr1 in K-562 cells



**Figure 3.** Cleavage of +30/-118 mdr1 fragment by alkylation with reactive derivated of LNA79 and ODN 79 followed by piperidine treatment. Lanes 1, 5—controls; 2, 6, the fragment incubated with LNA79-RCl in TE; 3, 7, the fragment incubated with LNA79-RCl in STE; 4, 8, A + G ladder. The target sequences are indicated by lines. [<sup>32</sup>P]-label at the 5' end on upper or lower strand of the fragment is marked by ☆.



**Figure 4.** In vivo down-regulation of *mdr1* expression by LNA79 ( $1 \times 10^{-6}$ M) in Hela cells. Lanes 1, 5, 9, control cells; lanes 2, 5, 10, cells treated by cytarabine; lanes 3, 6, 11, cells treated by doxorubicine; lanes 4, 7, 12, cells treated by vinblastine.



**Figure 5.** In vivo down-regulation of *mdr1* expression by LNA79 in K562 cells. Lanes 1, 5, 9, 13 – control cells; lanes 2, 5, 10, 14 – cells treated by cytarabine; lanes 3, 6, 11, 15 – cells treated by doxorubicine; lanes 4, 7, 12, 16 – cells treated by vinblastine.

while LNA77 and ODNs 77 and 79 did not influence *mdr1* activation. These data indicate, that LNA79 can be considered as a potential anti-*mdr1* compound.

## REFERENCES

1. Koshkin, A. A.; Singh, S. K.; Nielsen, P.; Rajwanshi, V. K.; Kumar, R.; Meldgaard, M.; Olsen, C. E.; Wengel, J. *Tetrahedron*, **1998**, *54* (14), 3607–3630.
2. Chaudhary, P. M.; Roninson, I. B.; *J. Natl. Cancer Inst.*, **1993**, *85*, 632–639.



## **Request Permission or Order Reprints Instantly!**

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

**[Order now!](#)**

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002443>